Libtayo - direct healthcare professional communication (DHPC)

cemiplimab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Libtayo (cemiplimab) 350 mg concentrate for solution for infusion: Batch / lot number and expiry date may become illegible following sanitisation and wiping of vial label

Key facts

• Medicine name:
  Libtayo
• Active substance:
  cemiplimab
• Therapeutic area (MeSH):
  Carcinoma, Squamous Cell
• DHPC type:
  Quality defect
• Human ATC codes:
  L01XC33
• Dissemination date:
  10/11/2025